Universität zu Köln

Journal Article

Herrlinger, Ulrich, Schaefer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Hau, Peter ORCID: 0000-0003-3894-5053, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W., Uhl, Martin, Maciaczyk, Jaroslaw, Grau, Stefan, Schnell, Oliver, Haenel, Mathias, Krex, Dietmar, Vajkoczy, Peter, Gerlach, Ruediger, Kortmann, Rolf-Dieter, Mehdorn, Maximilian, Tuettenberg, Jochen, Mayer-Steinacker, Regine, Fietkau, Rainer, Brehmer, Stefanie, Mack, Frederic, Stuplich, Moritz, Kebir, Sied, Kohnen, Ralf, Dunkl, Elmar, Leutgeb, Barbara, Proescholdt, Martin, Pietsch, Torsten, Urbach, Horst, Belka, Claus, Stummer, Walter and Glas, Martin (2016). Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O-6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J. Clin. Oncol., 34 (14). S. 1611 - 1623. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim, Schlegel, Uwe, Sabel, Michael, Hau, Peter, Kortman, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Baehr, Oliver, Uhl, Martin, Tabatabai, Ghazaleh, Ringel, Florian, Schmidt-Graf, Friederike, Brehmer, Stefanie, Weyerbrock, Astrid, Bullinger, Lars, Vajkoczy, Peter, Vatter, Hartmut, Schaefer, Niklas, Kebir, Sied, Weller, Johannes, Stummer, Walter, Simon, Matthias, Keil, Vera ORCID: 0000-0001-8699-3506, Nelles, Michael, Fimmers, Rolf, Pietsch, Torsten, Hattingen, Elke, Coch, Christoph and Glas, Martin (2017). PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial. Neuro-Oncology, 19. S. 13 - 15. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866

Herrlinger, Ulrich, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Sabel, Michael, Hau, Peter ORCID: 0000-0003-3894-5053, Kortmann, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Baehr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Kowalski, Thomas, Ringel, Florian, Schmidt-Graf, Friederike, Suchorska, Bogdana, Brehmer, Stefanie, Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Renovanz, Miriam, Bullinger, Lars, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Vajkoczy, Peter, Misch, Martin, Vatter, Hartmut, Stuplich, Moritz, Schaefer, Niklas, Kebir, Sied, Weller, Johannes ORCID: 0000-0001-5818-5392, Schaub, Christina, Stummer, Walter, Tonn, Joerg-Christian, Simon, Matthias, Keil, Vera C., Nelles, Michael, Urbach, Horst, Coenen, Martin, Wick, Wolfgang ORCID: 0000-0002-6171-634X, Weller, Michael, Fimmers, Rolf, Schmid, Matthias ORCID: 0000-0002-0788-0317, Hattingen, Elke ORCID: 0000-0002-8392-9004, Pietsch, Torsten, Coch, Christoph and Glas, Martin (2019). Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet, 393 (10172). S. 678 - 689. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-547X

Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke ORCID: 0000-0002-8392-9004, Schaefer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Weller, Johannes ORCID: 0000-0001-5818-5392, Mack, Frederic, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Baehr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Haenel, Mathias, Sabel, Michael, Gerlach, Ruediger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin and Herrlinger, Ulrich (2019). Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. J. Neuro-Oncol., 144 (3). S. 501 - 510. NEW YORK: SPRINGER. ISSN 1573-7373

Schaefer, Niklas, Proescholdt, Martin, Steinbach, Joachim P., Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Hau, Peter ORCID: 0000-0003-3894-5053, Grauer, Oliver, Goldbrunner, Roland, Friedrich, Franziska, Rohde, veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W., Uhl, Martin, Grau, Stefan, Haenel, Mathias, Schnell, Oliver, Krex, Dietmar, Vajkoczy, Peter, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Mack, Frederic, Schaub, Christina, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Niessen, Michael, Kebir, Sied, Leutgeb, Barbara, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin and Herrlinger, Ulrich (2018). Quality of life in the GLARIUS trial randomizing bevacizumab/ irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro-Oncology, 20 (7). S. 975 - 986. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866

Schaub, Christina, Kebir, Sied, Junold, Nina, Hattingen, Elke ORCID: 0000-0002-8392-9004, Schaefer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Hau, Peter ORCID: 0000-0003-3894-5053, Goldbrunner, Roland, Niessen, Michael, Mack, Frederic, Stuplich, Moritz, Tzaridis, Theophilos, Baehr, Oliver, Kortmann, Rolf-Dieter, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Braun, Christian, Haenel, Mathias, Sabel, Michael, Gerlach, Ruediger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Herrlinger, Ulrich and Glas, Martin (2018). Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. J. Cancer Res. Clin. Oncol., 144 (8). S. 1581 - 1590. NEW YORK: SPRINGER. ISSN 1432-1335

Scholz, Alexander, Harter, Patrick N. ORCID: 0000-0001-5530-6910, Cremer, Sebastian, Yalcin, Burak H., Gurnik, Stefanie, Yamaji, Maiko, Di Tacchio, Mariangela, Sommer, Kathleen, Baumgarten, Peter, Baehr, Oliver, Steinbach, Joachim P., Trojan, Joerg, Glas, Martin, Herrlinger, Ulrich, Krex, Dietmar, Meinhardt, Matthias, Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Timmer, Marco, Goldbrunner, Roland, Deckert, Martina, Braun, Christian, Schittenhelm, Jens, Frueh, Jochen T., Ullrich, Evelyn ORCID: 0000-0001-8530-1192, Mittelbronn, Michel, Plate, Karl H. and Reiss, Yvonne (2016). Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol. Med., 8 (1). S. 39 - 58. HOBOKEN: WILEY-BLACKWELL. ISSN 1757-4684

Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Schaefer, Niklas, Weller, Johannes, Steinbach, Joachim-Peter, Schlegel, Uwe, Seidel, Sabine, Sabel, Michael, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Tonn, Joerg-Christian, Grauer, Oliver, Kebir, Sied, Schneider, Matthias, Schaub, Christina, Vatter, Hartmut, Coch, Christoph, Glas, Martin, Fimmers, Rolf, Pietsch, Torsten, Reifenberger, Guido, Herrlinger, Ulrich and Felsberg, Joerg . MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial. Int. J. Cancer. HOBOKEN: WILEY. ISSN 1097-0215

Weller, Johannes ORCID: 0000-0001-5818-5392, Schaefer, Niklas, Schaub, Christina, Potthoff, Anna-Laura, Steinbach, Joachim P., Schlegel, Uwe, Sabel, Michael ORCID: 0009-0000-1485-7820, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Pietsch, Torsten, Tzaridis, Theophilos, Zeyen, Thomas, Borger, Valeri, Guresir, Erdem, Vatter, Hartmut, Herrlinger, Ulrich and Schneider, Matthias (2022). Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. J. Neuro-Oncol., 159 (1). S. 95 - 102. NEW YORK: SPRINGER. ISSN 1573-7373

Weller, Johannes ORCID: 0000-0001-5818-5392, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Baehr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Brehmer, Stefanie, Bullinger, Lars, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Schaub, Christina, Kebir, Sied, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich and Schaefer, Niklas (2019). Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol., 20 (10). S. 1444 - 1454. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Weller, Johannes, Tzaridis, Theophilos, Steinbach, Joachim, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Baehr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh, Bullinger, Lars, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Schaub, Christina, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Matthias, Schmid, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich and Schaefer, Niklas (2018). QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA. Neuro-Oncology, 20. S. 218 - 220. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866

Zeyen, Thomas, Potthoff, Anna-Laura, Nemeth, Robert, Heiland, Dieter H., Burger, Michael C., Steinbach, Joachim P., Hau, Peter, Tabatabai, Ghazaleh, Glas, Martin, Schlegel, Uwe, Grauer, Oliver, Krex, Dietmar, Schnell, Oliver, Goldbrunner, Roland, Sabel, Michael ORCID: 0009-0000-1485-7820, Thon, Niklas, Delev, Daniel, Clusmann, Hans, Seidel, Clemens, Gueresir, Erdem, Schmid, Matthias ORCID: 0000-0002-0788-0317, Schuss, Patrick ORCID: 0000-0002-5806-2576, Giordano, Frank A., Radbruch, Alexander, Becker, Albert, Weller, Johannes, Schaub, Christina, Vatter, Hartmut, Schilling, Judith, Winkler, Frank ORCID: 0000-0003-4892-6104, Herrlinger, Ulrich and Schneider, Matthias (2022). Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial. Trials, 23 (1). LONDON: BMC. ISSN 1745-6215